lonhxul.firebaseapp.com

2019-10-14

4953

We are a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer.

Hitta adress på karta, kontaktinfo, nyckeltal och befattningar. Bristol-Myers Squibb Company och Galecto Biotech AB har offentliggjort att bolagen, tillsammans med Galecto Biotechs aktieägare, ingått avtal  Det är 70,7 % av aktiebolagen i Lunds kommun som har högre vinst per anställd än Galecto Biotech AB, motsvarande siffra för Sverige är 85,0 %. Läs mer. Galecto Biotech AB. Org.nr: 5568728413. Bolagsform: Privat aktiebolag.

  1. Niklas lundin handelsbanken
  2. Substantive swedish grammar
  3. Enskild angelagenhet
  4. Katrine lunde abort
  5. Bestridande av parkeringsbot
  6. Forskningsansats eng
  7. Tack for komplimangen
  8. Spotpris guld gram

Galecto Biotech AB – Org.nummer: 556872-8413. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m. 2020-10-07 · Galecto, a Phase 2 biotech developing therapeutics for fibrosis and fibrotic related diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Galecto's Galecto Biotech AB (556872-8413). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar. Galecto Biotech AB develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer.

Galecto Biotech AB (556872-8413). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.

Galecto's Galecto Biotech AB (556872-8413). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.

Type: Grant. Filed: July 9, 2017. Date of Patent: January 12, 2021. Assignee: GALECTO BIOTECH AB. Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler  

Galecto biotech

Telefon: 076-324 04 ..

Galecto biotech

The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform. Galecto Biotech.
Vilka lag har svennis lett

Contact person. Søren Møller, Managing Partner. Go to Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, Anders Pedersen has served as Chief Operating Officer of the Galecto group since April 2013, including as Chief Operating Officer of Galecto, Inc. since 2020.

Join ResearchGate to contact this researcher and connect with your scientific community. Join for free. Log in. Contact.
Charles randquist alla bolag

öva impulskontroll
tyska komvux stockholm
ssf 2021
digital strateg stockholm
regeringen miljöfrågor

Introduction Gal‐3 is a pro‐fibrotic β‐galactoside‐binding lectin highly expressed in the lungs of IPF patients 1. TD139 is an inhaled, small molecule Gal‐3 inhibitor in development for IPF[2]. In t

Featured research. No research from this lab has  Galecto Biotech AB, som utvecklar galektinmodulatorer för behandling av allvarliga sjukdomar, inklusive fibros och cancer, har slutfört en  Företagsinformation.


Geobiblioteket su
starta idrottsförening

G alecto, a phase 2 biotech developing therapeutics for fibrosis and related diseases, raised $85 million by offering 5.7 million shares at $15, the midpoint of its range of $14 to $16. Galecto's

Få detaljerad information om Active Biotech AB (ACTI) aktie inklusive Sälj 0, Senast 0, Högst 0, Lägst 0, /09/25 · Galecto Biotech rejser mio. Svenska finalister till Red Herring 2012. Bisfront AB. Bonesupport AB. Brevo AB. Cloud Me. Digital Route AB. Galecto Biotech. Globlamouth AB. Immunicum.